Jun Watanabe

Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor

Daisuke Honma, Osamu Kanno, Jun Watanabe et al. · Cancer Science · 2017 · 139 citations · Full text

Medicine, Molecular Biology, Oncology +17

Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy

Yu Kanemaru, Manabu Natsumeda, Masayasu Okada et al. · Acta Neuropathologica Communications · 2019 · 69 citations · Full text

Medicine, Molecular Genetics, Oncology +16

High Detection Rate of <i>MYD88</i> Mutations in Cerebrospinal Fluid From Patients With CNS Lymphomas

Jun Watanabe, Manabu Natsumeda, Masayasu Okada et al. · JCO Precision Oncology · 2019 · 58 citations

Medicine, Molecular Genetics, Oncology +17

POU2AF2/C11orf53 functions as a coactivator of POU2F3 by maintaining chromatin accessibility and enhancer activity

Aileen Patricia Szczepanski, Natsumi Tsuboyama, Jun Watanabe et al. · Science Advances · 2022 · 51 citations · Full text

Life Sciences, Molecular Biology, Oncology +15

MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas

Hideaki Abe, Manabu Natsumeda, Masayasu Okada et al. · Frontiers in Oncology · 2020 · 44 citations · Full text

Medicine, Molecular Biology, Oncology +16